Latest News and Press Releases

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)...

The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients.The ongoing pilot study in cooperation with DEBRA...

Eleva is advancing CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of SAD evaluation in healthy volunteers

Avance Clinical Launches Dedicated Center of Excellence to Accelerate Early Phase Biotech Trials

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR...

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.

Ottawa, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The global rare disease treatment market size was valued at USD 195.21 billion in 2024 and is predicted to hit around USD 587.08 billion by 2034, rising at...

Soleo Health, a national provider of complex specialty pharmacy services, announced Holly Flax's promotion to Chief Operating Officer.

VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.

VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.